For example, Berlin et al. evaluated the use of bevacizumab (an anti-VEGF monoclonal antibody) with gemcitabine and radiotherapy in 127 patients with pancreatic adenocarcinoma, and complete tumour resection did not correlate with a better prognosis [64]. The gene discussed is VEGFA; the disease is pancreatic adenocarcinoma.